





























Richard Drury
Teva Pharmaceuticals (TEVA) and Swiss biotech Polpharma Biologics on Thursday announced an agreement under which the Israeli drugmaker will receive exclusive licensing rights to a biosimilar candidate targeting Roche’s (RHHBY) multiple sclerosis therapy Ocrevus.
As part of the deal, Teva (
此内容由惯性聚合(RSS阅读器)自动聚合整理,仅供阅读参考。 原文来自 — 版权归原作者所有。